These targeting agents aim to inhibit the tumor growth by interfering with specific proteins (cell signaling) involved in tumor progression, e.g. by blocking the signal transduction through Epidermal Growth Factor Receptor (EGFR), Vascular Endothelial Growth Factor (VEGF) or Anaplastic Lymphoma Kinase (ALK) gene. This evidence concerns the gene ALK and neoplasm.